Re2O. The ECM booster.

Developed and manufactured by L&C BIO in South Korea, Re2O brings human tissue-matrix expertise into an approach to skin quality.

Enquire about Re2O The expertise behind Re2O

The manufacturer

Tissue expertise that goes beyond aesthetics.

L&C BIO develops human tissue allografts (donated tissue prepared for use in another person), including dermal matrices for reconstructive surgery.

Its experience in working with donor tissue provides an established tissue-processing foundation behind Re2O. Re2O’s own clinical findings are covered separately on the research page.

From reconstructive surgery to skin quality.

Before Re2O, L&C BIO built its work around dermal matrices used in reconstructive surgery, where donated tissue is prepared to support repair in another person.

That portfolio is the background to Re2O: the same kind of tissue processing, applied to an aesthetic product. It shows experience with donor tissue. It does not, on its own, describe how Re2O performs.

How the tissue is sourced and checked

The Re2O range.

Re2O
150 mg acellular dermal matrix, according to the official catalogue.
Re2O Fine
50 mg acellular dermal matrix, according to the official English catalogue.

The published Re2O clinical study does not establish the results of Re2O Fine. Contact our team for current product information.

Your Re2O questions, answered locally.

This website is operated by DSquare Medical Sdn Bhd. Our Malaysia team can help with product information and enquiries from individuals and healthcare professionals.

L&C BIO makes Re2O. Whether a treatment suits you, and how it is planned, is for a qualified aesthetic doctor to decide.

DSquare Medical Sdn BhdWhatsApp +65 9816 4336

Let’s talk about your next step.

Tell us whether you're asking for yourself or for a clinic, and we'll route your enquiry to the right person.

I'm an individual I'm a healthcare professional Information for professionals

Is Re2O a stem-cell or hyaluronic acid product?

No. Re2O is a tissue-derived matrix material, not a stem-cell treatment and not hyaluronic acid alone. The published study used Re2O mixed with hyaluronic acid, so its results describe that combination.

Sources and product information

Humedix announced a distribution arrangement with L&C BIO for the Korean clinic market in November 2024.